China National Medicines Corporation Ltd. provided earnings guidance for the year 2017. The company predicts that the net profit belonging to shareholders of the listed company in 2017 will increase by between RMB 548 million and RMB 657 million with an increase of between 100% and 120% compared with the same period of the year before. The net profit belonging to shareholders of the listed company after excluding extraordinary profit and loss will increase by between RMB 405 million and RMB 513 million with an increase of between 75% and 95% compared with the same period of the year before. The company predicts that the net profit belonging to shareholders of the listed company in 2017 will increase by between RMB 100 million and RMB 198 million with an increase of between 10% and 20% compared with the same period of the year before after reiteration.